Type 2 diabetes (T2DM), affecting more than 530 million worldwide, is a metabolic disease often coupled with cardiovascular complications including coronary artery disease, heart failure, and stroke.
New research (the Ver-A-T1D trial) presented at this year’s Annual Meeting of the European Association for the Study of Diabetes (EASD) (Vienna, 15-19 September) shows that slow-release (SR) verapamil ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback